DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report)'s share price crossed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $9.63 and traded as high as $10.50. DBV Technologies shares last traded at $10.58, with a volume of 11,334 shares trading hands.
Wall Street Analyst Weigh In
Several brokerages have issued reports on DBVT. Citigroup reiterated an "outperform" rating on shares of DBV Technologies in a research report on Tuesday, May 27th. HC Wainwright lifted their target price on shares of DBV Technologies from $7.00 to $16.00 and gave the company a "buy" rating in a research report on Monday, May 5th. JMP Securities reiterated a "market outperform" rating and set a $21.00 target price on shares of DBV Technologies in a research report on Thursday, June 26th. Wall Street Zen upgraded shares of DBV Technologies from a "sell" rating to a "hold" rating in a research report on Saturday, July 5th. Finally, The Goldman Sachs Group upgraded shares of DBV Technologies to a "sell" rating and set a $7.25 target price for the company in a research report on Thursday, May 29th. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $14.75.
Get Our Latest Analysis on DBVT
DBV Technologies Price Performance
The stock has a market capitalization of $267.19 million, a PE ratio of -1.98 and a beta of -0.59. The firm's 50 day simple moving average is $9.65 and its 200 day simple moving average is $6.99.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC bought a new position in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies as of its most recent SEC filing. Institutional investors own 71.74% of the company's stock.
About DBV Technologies
(
Get Free Report)
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Featured Stories
Before you consider DBV Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.
While DBV Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
